Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio Inc (PALI) is a clinical-stage biopharmaceutical company advancing therapies focused on gastrointestinal health through intestinal barrier protection. This page provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Key resources include: Press releases detailing clinical trial progress, partnership announcements with research institutions, SEC filings, and updates on IBD treatment candidates. Our curated collection ensures efficient tracking of material events influencing the company’s trajectory.
Users will find updates categorized by clinical research advancements, intellectual property developments, and financial disclosures. Regular updates reflect Palisade Bio’s commitment to addressing ulcerative colitis, Crohn’s disease, and related inflammatory conditions through targeted therapeutic strategies.
Bookmark this page for streamlined access to verified PALI news. Combine our updates with Stock Titan’s financial tools for comprehensive market research.
Palisade Bio (NASDAQ: PALI) has successfully completed the Phase 1a portion of its Phase 1a/b study for PALI-2108, a treatment for Ulcerative Colitis (UC). The study included five Single Ascending Dose (SAD) cohorts, four Multiple Ascending Dose (MAD) cohorts, and food effects crossover.
Preliminary results showed promising safety data with no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs. Several MAD cohorts (15mg-30mg BID) were completed within the expected therapeutic dose range, with minimal adverse events. Only one withdrawal occurred in the highest 50mg twice-daily dosage cohort.
The company is currently screening and dosing patients for the Phase 1b UC cohort, with one subject having completed this portion. Topline data from Phase 1a is expected by May 2025, with complete Phase 1a/b results anticipated in the first half of 2025.
Palisade Bio (NASDAQ: PALI) has initiated dosing in the first Ulcerative Colitis (UC) patient cohort of its ongoing Phase 1a/b study for PALI-2108. The company has completed five single ascending dose (SAD) cohorts and three of four multiple ascending dose (MAD) cohorts, with promising preliminary safety data.
Key highlights include:
- No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs
- Majority of TEAEs were mild, with only one withdrawal at highest MAD dose
- Two MAD cohorts completed within expected therapeutic range showed excellent tolerability
The study aims to evaluate safety, tolerability, and pharmacokinetics in both healthy volunteers and UC patients. The trial will analyze various biomarkers including hsCRP, fecal calprotectin, and colonic tissue histological assessments. Topline data is expected in the first half of 2025.
Palisade Bio (NASDAQ: PALI) announced that two abstracts featuring its lead program PALI-2108 for ulcerative colitis treatment have been selected for presentation at Digestive Disease Week (DDW) 2025, scheduled for May 3-6 in San Diego.
The first presentation, focusing on bioinformatic approaches to PALI-2108 treatment in ulcerative colitis, will explore anti-fibrotic efficacy potential with local PDE4 inhibition in intestinal fibrosis. This session is scheduled for May 4, 2025.
The second abstract, recognized as a Poster of Distinction and rated in the top 10% of all AGA abstracts, will present findings on PALI-2108's colon-specific PDE4 inhibitor prodrug properties. The research demonstrates the drug's bioactivation in the colon, its dose-dependent reduction of colon tissue PDE4B, increased c-AMP, and TNF-α suppression in a mouse colitis model. This presentation is scheduled for May 5, 2025.
Palisade Bio (NASDAQ: PALI) has released a Virtual Investor 'What This Means' segment featuring Dr. Joerg Heyer, Head of Translational Science and Medicine. The segment focuses on the company's recent positive preclinical data for their lead product candidate, PALI-2108, which is being developed for the treatment of Ulcerative Colitis (UC).
The preclinical data was previously presented at the 2025 Crohn's and Colitis Congress. Dr. Heyer discusses the implications of these findings for Palisade's UC development program. The virtual segment is now available for viewing, along with other Virtual Investor events.
Palisade Bio (NASDAQ: PALI) has received CAD$1.39 million from Canada's Scientific Research and Experimental Development (SR&ED) Tax Credit Program through its co-development partner, Giiant Pharma. The funds reimburse pre-clinical development costs for PALI-2108, a treatment for Ulcerative Colitis (UC).
The company is currently conducting a Phase 1a/b single-center, double-blind, placebo-controlled study evaluating PALI-2108's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, along with an open-label study in UC patients. Topline data from this study is expected in the first half of 2025.
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO JD Finley presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.
Palisade Bio (NASDAQ: PALI) presented positive preclinical data for PALI-2108, their oral colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment, at the 2025 Crohn's and Colitis Congress. The drug demonstrated effectiveness in reducing colitis symptoms in mice without CNS toxicity.
Key findings showed that PALI-2108 effectively converts to the active PDE4 inhibitor PALI-0008 in the colon following oral administration in mice, dogs, and humans. The drug outperformed standard treatments in preclinical studies, showing superior potency and target engagement compared to other PDE4 inhibitors.
The company is currently conducting a Phase 1a/b clinical study (NCT06663605) evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and UC patients. Topline data is expected in the first half of 2025.
Palisade Bio (NASDAQ: PALI) announced the acceptance of its abstract for poster presentation at the 2025 Crohn's & Colitis Congress in San Francisco. The presentation, scheduled for February 7, 2025, will showcase research on PALI-2108, a colon-specific PDE4B inhibitor prodrug. The poster, titled 'PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model,' will be presented during the Poster and Exhibition Hall Reception at Moscone West.
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company specializing in autoimmune, inflammatory, and fibrotic diseases, has announced its upcoming participation in the LIVE! with Webull Corporate Connect: Healthcare Investment Webinar. JD Finley, the company's Chief Executive Officer, will present at the virtual event scheduled for Wednesday, January 29, 2025, at 2:20 PM ET.
The presentation will be part of the Virtual Biotech Investment Webinar segment of the conference, offering investors an opportunity to gain insights into Palisade Bio's developments and strategic direction in the healthcare sector.
Palisade Bio (NASDAQ: PALI) has successfully completed all five Single Ascending Dose (SAD) cohorts and advanced to Multiple Ascending Dose (MAD) cohorts in its Phase 1a/b study of PALI-2108 for Ulcerative Colitis treatment. The SAD study, testing doses from 15mg to 450mg, demonstrated favorable safety and tolerability with no serious adverse events or treatment-related laboratory abnormalities.
The preliminary pharmacokinetic analysis showed PALI-2108's delayed-release and extended-release characteristics, providing sustained, dose-dependent drug exposure with high local concentrations in the colon. Only mild treatment-emergent adverse events were observed at the highest dose of 450mg.
The ongoing MAD portion will assess repeat dosing and further evaluate safety and pharmacokinetics in both healthy volunteers and UC patients. The company remains on track to report topline data in the first half of 2025.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
